OncoMatch

OncoMatch/Clinical Trials/NCT05511623

Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer

Is NCT05511623 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies tislelizumab for cervical cancer.

Phase 2RecruitingFirst Affiliated Hospital of Guangxi Medical UniversityNCT05511623Data as of Jun 2026Location: China

Treatment: tislelizumabTo evaluate the efficacy and safety of tislelizumab combined with concurrent chemoradiotherapy in first-line treatment of stage IIIC2 cervical cancer.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Immunotherapy

tislelizumab

Cancer type

Cervical Cancer

Disease stage

Required: Stage IIIC2

Performance status

ECOG 0–1(Restricted strenuous activity)

Demographics

Ages ≤ 70
Female only

Prior therapy

Cannot have received: anti-PD-1 therapy

Previously treatment with PD-1 and/or PD-L1, or CTLA-4 antibody, or other medications targeting immunomodulatory receptors

Lab requirements

Blood counts

hemoglobin ≥90g/L, neutrophils ≥1.5×10^9/L, platelets ≥80×10^9/L

Kidney function

Creatinine clearance ≥60 mL/min

Liver function

Total bilirubin ≤1.5 x institutional upper limit of normal, AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal, ALB≥30g/L

Participants must have normal organ and marrow function as defined below: (hemoglobin ≥90g/L, neutrophils ≥1.5×10^9/L, platelets ≥80×10^9/L, ALB≥30g/L, Total bilirubin≤1.5 x institutional upper limit of normal, AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal, Creatinine clearance≥60 mL/min

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT05511623 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior anti-PD-1 therapy disqualifies patients from enrollment.

What disease stage is eligible?

Stage IIIC2 is required.

Is there an age limit?

Yes. Patients must be 70 years or younger.

Is this trial open to male patients?

No. This trial enrolls female patients only.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify